The Department of Health (DH) launched a consultation on revisions to the statutory scheme to control prices of branded medicine used on the NHS, which includes drugs not priced using the country's Pharmaceutical Price Regulation Scheme (PPRS) – a voluntary system to negotiate drug prices through industry/ government negotiation.
This statutory price control scheme was launched in 2008 to provide price controls for NHS medicines for companies who choose to opt out of PPRS.
Proposals in the consultation include a price adjustment on sales of branded drugs to the NHS of between 10 and 20 per cent while adding an exemption for smaller companies that have UK NHS sales of branded medicines of less than £5m.
“We want to make sure we get the best possible outcomes for all NHS patients with the resources we have,” said health minister Lord Howe in a statement announcing the consultation.
“We cannot simply spend more and more on drugs – this would mean spending less and less elsewhere.”
Anyone wanting to respond to the proposals has until July 31, 2013, when the consultation period closes.
The plans come at a time when the DH is looking to replace PPRS with a value-based pricing (VBP) system for new drugs from January 2014, and the DH expanded on these plans in its statement.